Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Pasithea Therapeutics Corp.
  6. Financials
    KTTA   US70261F1030

PASITHEA THERAPEUTICS CORP.

(KTTA)
  Report
Delayed Nasdaq  -  05/23 01:27:02 pm EDT
0.9000 USD   +0.56%
05/16PASITHEA THERAPEUTICS CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
05/16Pasithea Therapeutics Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/14Pasithea Therapeutics to Present at the NobleCon18 Investor Conference 2022
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2021 2022 2023
Capitalization1 38,720,8-
Enterprise Value (EV)1 -14,220,820,8
P/E ratio ---
Yield ---
Capitalization / Revenue 2 573x8,34x4,17x
EV / Revenue 2 573x8,34x4,17x
EV / EBITDA -8,60x-4,01x-4,17x
Price to Book ---
Nbr of stocks (in thousands) 21 88823 288-
Reference price (USD) 1,770,900,90
Announcement Date 03/30/2022--
1 USD in Million
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2020 2021 2022 2023
Net sales1 -0,022,505,00
EBITDA1 --4,51-5,20-5,00
Operating profit (EBIT) --4,51--
Operating Margin --29 930%--
Pre-Tax Profit (EBT) ----
Net income -0,04---
Net margin ----
EPS ----
Dividend per Share ----
Announcement Date 04/13/202103/30/2022--
1 USD in Million
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4
Net sales1 0,020,010,500,801,00
EBITDA1 --2,40-1,20-1,20-1,20
Operating profit (EBIT) -1,96----
Operating Margin -12 990%----
Pre-Tax Profit (EBT) -----
Net income -----
Net margin -----
EPS -----
Dividend per Share -----
Announcement Date 03/30/202205/16/2022---
1 USD in Million
Estimates
Balance Sheet Analysis
Fiscal Period: December 2020 2021 2022 2023
Net Debt ----
Net Cash position -53,0--
Leverage (Debt / EBITDA) -11,8x--
Free Cash Flow --3,20--
ROE (Net Profit / Equities) ----
Shareholders' equity ----
ROA (Net Profit / Asset) ----
Assets ----
Book Value Per Share ----
Cash Flow per Share ----
Capex -0,02--
Capex / Sales -143%--
Announcement Date 04/13/202103/30/2022--
Estimates
Key data
Capitalization (USD) 20 842 597
Net sales (USD) 15 060
Number of employees 4
Sales / Employee (USD) 3 765
Free-Float 90,3%
Free-Float capitalization (USD) 18 822 928
Avg. Exchange 20 sessions (USD) 128 181
Average Daily Capital Traded 0,61%
EPS & Dividend